m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05897
 [1]
m6A modification Circ_ASXL1 Circ_ASXL1 IGF2BP1 : m6A sites Indirect Inhibition Non-coding RNA miR-320d RACGAP1  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
m6A Target Circ_ASXL1
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-320d microRNA View Details
Regulated Target Rac GTPase-activating protein 1 (RACGAP1) View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators indirectly modulate the functionality of ncRNAs through downstream signaling pathways
Crosstalk Summary METTL3/IGF2BP1-mediated m6A modification maintained Circ_ASXL1 stability and upregulated its expression. CircASXL1 was a ceRNA that sequestrated hsa-miR-320d from Rac GTPase-activating protein 1 (RACGAP1), leading to increased RACGAP1 expression. CircASXL1 promoted OC cell proliferation, migration and invasion via the miR-320d/RACGAP1 axis.
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Cell Process Cell proliferation, Cell migration
Cell invasion
In-vitro Model
 SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
ES-2 Ovarian clear cell adenocarcinoma Homo sapiens CVCL_3509
HEY Ovarian serous adenocarcinoma Homo sapiens CVCL_0297
A2780 Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_0134
COV362 Ovarian serous adenocarcinoma Homo sapiens CVCL_2420
In-vivo Model SKOV3 cells were treated with sh-NC or sh-circASXL1. 100 μL of PBS containing 1 × 106 cells were implanted into mice. Tumor volume was measured every 5 days. After 30 days, mice were euthanized. The tumor was excised and weighed.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C73: Ovarian cancer 198 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Atezolizumab Approved [2]
External Link
TTD: D0YM2K
 Compound Name Carboplatin Approved [3]
Synonyms
Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
    Click to Show/Hide
External Link
CID: 426756
TTD: D0X7HM
 Compound Name Lurbinectedin Phase 3 [4]
Synonyms
UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B
    Click to Show/Hide
External Link
CID: 57327016
TTD: D0V6OA
DrugBank: DB12674
 Compound Name Mirvetuximab soravtansine Approved [2]
Synonyms
ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489
    Click to Show/Hide
External Link
CID: 91810695
TTD: D0RP2W
 Compound Name Lenvatinib Approved [5]
Synonyms
E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 9823820
TTD: D0R0FO
DrugBank: DB09078
 Compound Name Catumaxomab Phase 2 [6]
External Link
TTD: D0O5ER
 Compound Name Avelumab Approved [2]
External Link
TTD: D0K7SX
 Compound Name Olaparib Approved [2]
Synonyms
AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
    Click to Show/Hide
External Link
CID: 23725625
TTD: D0J9HW
DrugBank: DB09074
 Compound Name Cabozantinib Approved [7]
Synonyms
Cabometyx; Cometriq
    Click to Show/Hide
External Link
CID: 25102847
TTD: D0IQ6P
DrugBank: DB08875
 Compound Name Taxol Approved [8]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Tisotumab vedotin Phase 2 [9]
External Link
TTD: D0A4GQ
 Compound Name KU-0058948 Approved [10]
Synonyms
CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
    Click to Show/Hide
External Link
CID: 11291932
TTD: D09LSX
DrugBank: DB08058
 Compound Name MVax Approved [11]
Synonyms
MVax (TN)
    Click to Show/Hide
External Link
TTD: D09JNP
 Compound Name Intedanib Phase 2 [12]
Synonyms
Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate
    Click to Show/Hide
External Link
CID: 135423438
TTD: D09HNV
DrugBank: DB09079
 Compound Name Fluzone QIV Approved [11]
Synonyms
Seasonal influenza vaccine (quadrivalent)
    Click to Show/Hide
External Link
TTD: D09FHM
 Compound Name Pembrolizumab Approved [2]
External Link
TTD: D08ANZ
 Compound Name Plicamycin Approved [13]
Synonyms
A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01
    Click to Show/Hide
External Link
CID: 163659
TTD: D06EPF
DrugBank: DB06810
 Compound Name Bevacizumab Approved [2]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name Trabectedin Approved [2]
Synonyms
Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)
    Click to Show/Hide
External Link
CID: 108150
TTD: D03RTK
DrugBank: DB05109
 Compound Name Topotecan Approved [14]
Synonyms
Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin
    Click to Show/Hide
External Link
CID: 60700
TTD: D02PMO
DrugBank: DB01030
 Compound Name Altretamine Approved [15]
Synonyms
Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
    Click to Show/Hide
External Link
CID: 2123
TTD: D02LPF
DrugBank: DB00488
 Compound Name Rucaparib Approved [16]
Synonyms
283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
    Click to Show/Hide
External Link
CID: 9931954
TTD: D01SHZ
DrugBank: DB12332
 Compound Name Melphalan flufenamide Approved [17]
Synonyms
J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides
    Click to Show/Hide
External Link
CID: 9935639
TTD: D01HPY
 Compound Name Nivolumab Approved [2]
External Link
TTD: D00GOV
 Compound Name Ofranergene obadenovec Phase 3 [18]
Synonyms
VB-111
    Click to Show/Hide
External Link
TTD: DU60ND
 Compound Name Batiraxcept Phase 3 [19]
Synonyms
AVB-S6-500
    Click to Show/Hide
External Link
TTD: DDRX30
 Compound Name Trebananib Phase 3 [20]
External Link
TTD: D9NL3R
 Compound Name Nemvaleukin alfa Phase 3 [21]
External Link
TTD: D1I0LQ
 Compound Name RRx-001 Phase 2 [2]
Synonyms
925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015
    Click to Show/Hide
External Link
CID: 15950826
TTD: D0X8TS
DrugBank: DB12060
 Compound Name Picoplatin Phase 3 [22]
Synonyms
AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride
    Click to Show/Hide
External Link
CID: 177358
TTD: D0T7GV
DrugBank: DB04874
 Compound Name VB-111 Phase 3 [2]
External Link
TTD: D0S4LV
 Compound Name Upifitamab rilsodotin Phase 3 [23]
External Link
TTD: D0QFD2
 Compound Name ABT-888 Phase 3 [2]
Synonyms
Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride
    Click to Show/Hide
External Link
CID: 45480520
TTD: D0Q7UD
 Compound Name Rubraca rucaparib Phase 3 [2]
External Link
TTD: D0NA8B
 Compound Name Masitinib Phase 3 [2]
Synonyms
790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
    Click to Show/Hide
External Link
CID: 10074640
TTD: D0MW0N
DrugBank: DB11526
 Compound Name Galinpepimut-S Phase 3 [24]
External Link
TTD: D0M9OO
 Compound Name SNDX-275 Phase 3 [2]
Synonyms
Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
    Click to Show/Hide
External Link
CID: 4261
TTD: D0M8FD
DrugBank: DB11841
 Compound Name acelarin Phase 2 [2]
Synonyms
NUC-1031
    Click to Show/Hide
External Link
CID: 11169170
TTD: D0M1IN
DrugBank: DB15057
 Compound Name Glufosfamide Phase 3 [5]
Synonyms
Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
    Click to Show/Hide
External Link
CID: 123628
TTD: D0L9IA
DrugBank: DB06177
 Compound Name PM1183 Phase 3 [8]
External Link
TTD: D0K6AL
 Compound Name Amonafide Phase 3 [25]
Synonyms
Quinamed (TN)
    Click to Show/Hide
External Link
CID: 50515
TTD: D0HR7P
DrugBank: DB05022
 Compound Name Etirinotecan pegol Phase 2 [8]
Synonyms
NKTR-102
    Click to Show/Hide
External Link
CID: 56935717
TTD: D0H5IZ
 Compound Name INCB24360 Phase 2 [2]
Synonyms
Epacadostat
    Click to Show/Hide
External Link
CID: 135564890
TTD: D0G7MV
DrugBank: DB11717
 Compound Name AL3818 Phase 1/2 [2]
Synonyms
Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
    Click to Show/Hide
External Link
CID: 25017411
TTD: D0G2CG
DrugBank: DB11885
 Compound Name Sapacitabine Phase 3 [2]
Synonyms
CYC682
    Click to Show/Hide
External Link
CID: 153970
TTD: D0D4RF
DrugBank: DB06365
 Compound Name Pelareorep Phase 2 [8]
External Link
TTD: D0BF8Y
 Compound Name Opdivo + Yervoynivolumab + ipilimumab Phase 1/2 [2]
External Link
TTD: D08TBK
 Compound Name Epothilon Phase 3 [5]
External Link
TTD: D07WPE
 Compound Name Oregovomab Phase 3 [26]
External Link
TTD: D07HUW
 Compound Name Farletuzumab Phase 3 [27]
External Link
TTD: D06XVN
 Compound Name DCVax-Ovarian Phase 3 [2]
Synonyms
DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D02XEI
 Compound Name MK-8109 Phase 3 [28]
External Link
TTD: D02TJT
 Compound Name Karenitecin Phase 3 [29]
Synonyms
Karenitecin (TN)
    Click to Show/Hide
External Link
CID: 148202
TTD: D02CZK
DrugBank: DB05806
 Compound Name TRC105 Phase 2 [30]
External Link
TTD: D00YQI
 Compound Name SNS-595 Phase 3 [5]
Synonyms
Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Click to Show/Hide
External Link
CID: 9952884
TTD: D00NVM
DrugBank: DB11999
 Compound Name MK-4827 Phase 3 [31]
Synonyms
1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
    Click to Show/Hide
External Link
CID: 24958200
TTD: D00BMF
DrugBank: DB11793
 Compound Name EC20 Phase 3 [32]
Synonyms
Technetium Tc-99m etarfolatide
    Click to Show/Hide
External Link
CID: 135428923
TTD: D00BHL
 Compound Name Abagovomab Phase 2/3 [33]
External Link
TTD: D00KGB
 Compound Name Mecbotamab vedotin Phase 2 [34]
Synonyms
HTBA3011; HTBA3012
    Click to Show/Hide
External Link
TTD: DYI4L2
 Compound Name GEN-1 Phase 2 [2]
External Link
TTD: DRT2P7
 Compound Name Stenoparib Phase 2 [35]
External Link
TTD: DP48WE
 Compound Name DKN-01 Phase 2 [2]
External Link
TTD: DMF73Z
 Compound Name EP-100 Phase 2 [2]
External Link
TTD: DL76CW
 Compound Name EP0057 Phase 2 [36]
Synonyms
CRLX101
    Click to Show/Hide
External Link
TTD: DGD93X
 Compound Name BNT141 Phase 2 [37]
External Link
TTD: DFZ19J
 Compound Name TJ004309 Phase 2 [38]
External Link
TTD: DFYL50
 Compound Name Maveropepimut-S Phase 2 [39]
External Link
TTD: DFS8A7
 Compound Name PF-07901801 Phase 2 [40]
Synonyms
maplirpacept
    Click to Show/Hide
External Link
TTD: D6SJ0B
 Compound Name SPL-108 Phase 2 [2]
External Link
TTD: D2C0DY
 Compound Name VS-6063 Phase 2 [2]
Synonyms
Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu
    Click to Show/Hide
External Link
CID: 25117126
TTD: D0Y1UO
DrugBank: DB12282
 Compound Name PTX-200 Phase 2 [2]
Synonyms
Plant-derived antiparkinsonian, Phytrix
    Click to Show/Hide
External Link
TTD: D0X7CV
 Compound Name Mirvetuximab soratansine Phase 2 [8]
External Link
TTD: D0V9EX
 Compound Name Ovapuldencel-T Phase 2 [2]
External Link
TTD: D0TR3Y
 Compound Name MUC-1 cancer vaccine Phase 2 [41]
Synonyms
CVac (TN)
    Click to Show/Hide
External Link
TTD: D0T5ES
 Compound Name FANG vaccine Phase 3 [42]
Synonyms
FANG (TN)
    Click to Show/Hide
External Link
TTD: D0Q4NX
 Compound Name Ispinesib Phase 2 [43]
Synonyms
SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
    Click to Show/Hide
External Link
CID: 6851740
TTD: D0PW4N
DrugBank: DB06188
 Compound Name EGEN-001 Phase 2 [44]
External Link
TTD: D0OS7K
 Compound Name CRLX101 Phase 2 [2]
External Link
CID: 184196
TTD: D0ND9T
 Compound Name Folate binding protein vaccine Phase 2 [45]
External Link
TTD: D0M7YU
 Compound Name RO-5126766 Phase 2 [46]
Synonyms
VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche
    Click to Show/Hide
External Link
CID: 16719221
TTD: D0M6BD
DrugBank: DB15254
 Compound Name TPIV200 Phase 2 [24]
External Link
TTD: D0LB8Z
 Compound Name BBI503 Phase 2 [47]
External Link
CID: 25190990
TTD: D0L9XF
DrugBank: DB14866
 Compound Name Varlilumab Phase 2 [2]
External Link
TTD: D0KV3M
 Compound Name Kevetrin Phase 2 [2]
External Link
CID: 437740
TTD: D0K7DV
DrugBank: DB13010
 Compound Name OTL38 Phase 2 [8]
External Link
TTD: D0I9IL
 Compound Name NanoPac Phase 2 [2]
External Link
TTD: D0FZ7Q
 Compound Name Sagopilone Phase 2 [48]
Synonyms
ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
    Click to Show/Hide
External Link
CID: 11284169
TTD: D0F6YW
DrugBank: DB12391
 Compound Name PMID27841036-Compound-37 Phase 2 [49]
Synonyms
2X-121
    Click to Show/Hide
External Link
CID: 135565981
TTD: D0F5TD
 Compound Name BGB-290 Phase 2 [50]
Synonyms
Pamiparib
    Click to Show/Hide
External Link
CID: 135565554
TTD: D0D9IQ
DrugBank: DB14769
 Compound Name TLPLDC Phase 2 [24]
External Link
TTD: D0D0DH
 Compound Name Anetumab ravtansine Phase 2 [2]
Synonyms
Mesothelin-ADC
    Click to Show/Hide
External Link
TTD: D0CN9D
 Compound Name OGX-427 Phase 2 [51]
External Link
CID: 71710946
TTD: D0AX1N
 Compound Name ZW25 Phase 1 [2]
Synonyms
Zanidatamab
    Click to Show/Hide
External Link
TTD: D0AJ9V
 Compound Name CDX-1401 Phase 2 [2]
External Link
TTD: D09TCY
 Compound Name CA4P Phase 2 [8]
Synonyms
Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr
    Click to Show/Hide
External Link
CID: 100154
TTD: D09OKZ
DrugBank: DB05284
 Compound Name Dendritic cell vaccine Phase 2 [52]
Synonyms
Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn
    Click to Show/Hide
External Link
TTD: D09NFW
 Compound Name LY2606368 Phase 2 [2]
Synonyms
prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013
    Click to Show/Hide
External Link
CID: 46700756
TTD: D08UUL
DrugBank: DB12008
 Compound Name GSK3377794 Phase 2 [2]
External Link
TTD: D08FWJ
 Compound Name Melphalan Approved [53]
External Link
CID: 460612
TTD: D06XES
DrugBank: DB01042
 Compound Name MEDI-546 Phase 2 [54]
External Link
TTD: D06TME
 Compound Name RG-7599 Phase 2 [55]
Synonyms
DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech
    Click to Show/Hide
External Link
TTD: D05YYP
 Compound Name EP-201 Phase 2 [24]
Synonyms
Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec
    Click to Show/Hide
External Link
CID: 61094
TTD: D05GYU
 Compound Name APR-246 Phase 2 [2]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name Tigatuzumab Phase 2 [56]
External Link
TTD: D03LTO
 Compound Name CRS-207 Phase 2 [24]
External Link
TTD: D02WSB
 Compound Name MK-1775 Phase 2 [57]
Synonyms
955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219
    Click to Show/Hide
External Link
CID: 24856436
TTD: D02KKA
DrugBank: DB11740
 Compound Name CP-547632 Phase 2 [58]
Synonyms
BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide
    Click to Show/Hide
External Link
CID: 9811611
TTD: D00YPR
DrugBank: DB12962
 Compound Name Motolimid Phase 2 [8]
External Link
TTD: D00OYC
 Compound Name TC-210 Phase 1/2 [59]
External Link
TTD: DX6O9V
 Compound Name REGN5668 Phase 1/2 [60]
External Link
TTD: DT1R9E
 Compound Name TC-510 Phase 1/2 [61]
External Link
TTD: DJA64B
 Compound Name XMT-1592 Phase 1/2 [62]
External Link
TTD: DDL79K
 Compound Name GL-ONC1 Phase 2 [63]
Synonyms
olvimulogene nanivacirepvec
    Click to Show/Hide
External Link
TTD: DA6OU0
 Compound Name LY2940680 Phase 1/2 [2]
Synonyms
1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]
    Click to Show/Hide
External Link
CID: 49848070
TTD: D0W0SL
DrugBank: DB12550
 Compound Name Her-2/neu vaccine Phase 1/2 [64]
External Link
TTD: D0U3FP
 Compound Name NY-ESO-TCR Phase 1/2 [65]
External Link
TTD: D0TN1N
 Compound Name GALE-302 Phase 1/2 [2]
External Link
TTD: D0T7MZ
 Compound Name DPX-survivac cancer vaccine Phase 1/2 [66]
External Link
TTD: D0T2IF
 Compound Name REGN4018 Phase 1/2 [67]
External Link
TTD: D0LA9K
 Compound Name GALE-301 + GALE-302 Phase 1/2 [24]
External Link
TTD: D0IW4E
 Compound Name Anti-C-met CAR-T cells Phase 1/2 [68]
External Link
TTD: D0A3OE
 Compound Name CDX-014 Phase 1/2 [2]
External Link
TTD: D09WXY
 Compound Name O-Vax Phase 1/2 [69]
Synonyms
AC vaccine (ovarian cancer), AVAX
    Click to Show/Hide
External Link
TTD: D09GRH
 Compound Name Anti-HER2 CAR-T Phase 1/2 [70]
External Link
TTD: D08QZH
 Compound Name NT-501 CNTF Phase 1/2 [71]
External Link
TTD: D07GWZ
 Compound Name Phenoxodiol Phase 1/2 [72]
Synonyms
Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran
    Click to Show/Hide
External Link
CID: 219100
TTD: D03YOS
DrugBank: DB04915
 Compound Name GALE-301 Phase 2 [24]
External Link
TTD: D02DEZ
 Compound Name IL-2/gene-modified lymphocytes Phase 1/2 [73]
External Link
TTD: D01VWB
 Compound Name Ovarian dendritic cell-based vaccine Phase 1/2 [74]
External Link
TTD: D01EMD
 Compound Name Anti-mesothelin CAR transduced PBL Phase 1/2 [75]
External Link
TTD: D00YXG
 Compound Name ONCOS-102 Phase 1/2 [2]
Synonyms
CGTG-102
    Click to Show/Hide
External Link
TTD: D00NBW
 Compound Name BNT115 Phase 1 [76]
External Link
TTD: DT3OZ4
 Compound Name MEDI3617 Phase 1 [77]
External Link
TTD: DP7J0Z
 Compound Name SL-172154 Phase 1 [78]
External Link
TTD: DKUF26
 Compound Name INKmune Phase 1 [79]
External Link
TTD: DJ9H4F
 Compound Name DeTIL-0255 Phase 1 [80]
External Link
TTD: DJ3QK6
 Compound Name DS-6000 Phase 1 [81]
External Link
TTD: DISJ28
 Compound Name MCY-M11 Phase 1 [82]
External Link
TTD: D8EIB7
 Compound Name IMT1012 Phase 1 [83]
External Link
TTD: D7W6SO
 Compound Name mRNA-2416 Phase 1 [84]
Synonyms
mRNA-OX40L
    Click to Show/Hide
External Link
TTD: D70SHJ
 Compound Name TG4050 Phase 1 [85]
External Link
TTD: D6CV1Q
 Compound Name GRN-300 Phase 1 [86]
External Link
TTD: D40NQW
 Compound Name ITIL-306 Phase 1 [87]
External Link
TTD: D3MGD9
 Compound Name STRO-002 Phase 1 [88]
External Link
TTD: D10GPJ
 Compound Name Ipafricept Phase 1 [89]
External Link
TTD: D0Z6AM
 Compound Name IMT-1012 immunotherapeutic vaccine Phase 1 [90]
External Link
TTD: D0Y9VC
 Compound Name STM 434 Phase 1 [8]
External Link
TTD: D0X6DC
 Compound Name Mibefradil Withdrawn from market [91]
Synonyms
Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
    Click to Show/Hide
External Link
CID: 60663
TTD: D0W8XT
DrugBank: DB01388
 Compound Name RG7882 Phase 1 [92]
External Link
TTD: D0V7QW
 Compound Name MOv19-BBz CAR T cells Phase 1 [93]
External Link
TTD: D0T7CR
 Compound Name SC-003 Phase 1 [2]
External Link
TTD: D0SZ2G
 Compound Name KHK-2866 Phase 1 [94]
External Link
TTD: D0S4KJ
 Compound Name PUMVC3-hIGFBP-2 Phase 1 [95]
Synonyms
IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson
    Click to Show/Hide
External Link
TTD: D0O9FH
 Compound Name Anti-hCD70 CAR transduced PBL Phase 1 [96]
External Link
TTD: D0JO9M
 Compound Name Prolanta Phase 1 [2]
External Link
TTD: D0J1OG
 Compound Name JCAR020 Phase 1 [65]
External Link
TTD: D0I0FA
 Compound Name COTI-2 Phase 1 [2]
Synonyms
UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
    Click to Show/Hide
External Link
CID: 91810660
TTD: D0G8CU
 Compound Name Anti-meso-CAR vector transduced T cells Phase 1 [97]
External Link
TTD: D0G4GY
 Compound Name Cantrixil Phase 1 [2]
Synonyms
UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2
    Click to Show/Hide
External Link
CID: 129851403
TTD: D0FL2K
 Compound Name Iboctadekin + Doxil Phase 1 [98]
External Link
CID: 5478883
TTD: D0F3PU
 Compound Name FATE-NK100 Phase 1 [2]
External Link
TTD: D0A9GE
 Compound Name Iboctadekin Phase 1 [99]
External Link
TTD: D0A8HN
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [100]
External Link
TTD: D09HRH
 Compound Name Hu-CART meso cells Phase 1 [101]
External Link
TTD: D07YPB
 Compound Name PTC596 Phase 1 [2]
External Link
TTD: D07EKK
 Compound Name SOR-C13 Phase 1 [102]
External Link
CID: 121596688
TTD: D06UWF
DrugBank: DB15366
 Compound Name AE-O Phase 1 [103]
Synonyms
Ovarian vaccine, Generex
    Click to Show/Hide
External Link
TTD: D05MEP
 Compound Name E 7974 Phase 1 [5]
Synonyms
26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872
    Click to Show/Hide
External Link
CID: 10127315
TTD: D05HBZ
 Compound Name DMUC-5754A Phase 1 [104]
External Link
TTD: D04ZIZ
 Compound Name Alvespimycin hydrochloride Phase 1 [105]
Synonyms
Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG
    Click to Show/Hide
External Link
CID: 9852573
TTD: D03LRU
 Compound Name Navicixizumab Phase 1 [65]
External Link
TTD: D00IVN
 Compound Name AR-A014418 Patented [106]
Synonyms
487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N& -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be
    Click to Show/Hide
External Link
CID: 448014
TTD: D0A3MV
DrugBank: DB01950
 Compound Name R1549 Discontinued in Phase 3 [107]
External Link
TTD: D0VE6X
 Compound Name Tanomastat Discontinued in Phase 3 [108]
Synonyms
Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
    Click to Show/Hide
External Link
CID: 6918336
TTD: D0Q1CD
DrugBank: DB06276
 Compound Name IDM-1 Discontinued in Phase 3 [109]
Synonyms
Osidem
    Click to Show/Hide
External Link
TTD: D02YWW
 Compound Name Lurtotecan Discontinued in Phase 2 [110]
Synonyms
OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan
    Click to Show/Hide
External Link
CID: 60956
TTD: D0Q7FC
DrugBank: DB12222
 Compound Name AGS-8M4 Discontinued in Phase 2 [111]
Synonyms
AGS-8 MAb, Agensys, AGS8M4, ASP-6183
    Click to Show/Hide
External Link
TTD: D05DBZ
 Compound Name Biricodar Discontinued in Phase 2 [112]
Synonyms
Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
    Click to Show/Hide
External Link
CID: 3037617
TTD: D02VJY
DrugBank: DB04851
 Compound Name Onyvax-O Discontinued in Phase 1 [113]
External Link
TTD: D0XT5F
 Compound Name RG7458 Discontinued in Phase 1 [114]
External Link
TTD: D0G9ZJ
 Compound Name RG7600 Discontinued in Phase 1 [115]
External Link
TTD: D04TYP
 Compound Name S-8184 Preclinical [116]
External Link
TTD: D0X4UH
 Compound Name 111In-OC-125 F(ab1/2)-DTPA Terminated [117]
Synonyms
Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA
    Click to Show/Hide
External Link
TTD: D07PMU
 Compound Name HumaRAD-OV Investigative [118]
Synonyms
HumaRAD88BV59; KSB-310
    Click to Show/Hide
External Link
TTD: D0Z1CQ
 Compound Name FOLIGO 002 Investigative [118]
External Link
TTD: D0Y6QX
 Compound Name HS-210 Investigative [118]
Synonyms
HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics
    Click to Show/Hide
External Link
TTD: D0XK6P
 Compound Name CGEN-991 Investigative [118]
Synonyms
Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen
    Click to Show/Hide
External Link
TTD: D0V1TV
 Compound Name FabOvar Investigative [118]
Synonyms
Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe
    Click to Show/Hide
External Link
TTD: D0S6OY
 Compound Name ALVAC-CEA/hB7.1 Investigative [118]
External Link
TTD: D0Q2IV
 Compound Name MX-35 Investigative [118]
Synonyms
Monoclonal antibody (ovarian cancer), Recepta
    Click to Show/Hide
External Link
TTD: D0P6YL
 Compound Name 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Investigative [119]
Synonyms
CHEMBL1082330; BDBM50320180
    Click to Show/Hide
External Link
CID: 46891330
TTD: D0OQ5H
 Compound Name ET-006 Investigative [118]
External Link
TTD: D0L3LO
 Compound Name AB-3D3 Investigative [118]
Synonyms
AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia
    Click to Show/Hide
External Link
TTD: D0F6DF
 Compound Name RAP-701 Investigative [118]
Synonyms
Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0CO3O
 Compound Name Anti-folate receptor 1 humanized mab Investigative [118]
Synonyms
Anti-folate receptor 1 humanized mAb (cancer)
    Click to Show/Hide
External Link
TTD: D09IVP
 Compound Name Disorazol Z-LHRH conjugates Investigative [118]
Synonyms
Disorazol Z-LHRH conjugates (ovarian cancer)
    Click to Show/Hide
External Link
TTD: D08LRU
 Compound Name Anti-CGEN-153 mab Investigative [118]
Synonyms
CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen
    Click to Show/Hide
External Link
TTD: D08ENJ
 Compound Name OGX-427 + Paclitaxel Investigative [120]
External Link
CID: 91866823
TTD: D00ZBZ
References
Ref 1 m6A-modified circASXL1 promotes proliferation and migration of ovarian cancer through the miR-320d/RACGAP1 axis. Carcinogenesis. 2023 Dec 30;44(12):859-870. doi: 10.1093/carcin/bgad066.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
Ref 4 ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
Ref 5 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
Ref 6 ClinicalTrials.gov (NCT00377429) Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy. U.S. National Institutes of Health.
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 9 ClinicalTrials.gov (NCT03245736) Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.. U.S. National Institutes of Health.
Ref 10 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. doi: 10.1038/nrd4545.
Ref 11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
Ref 13 The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
Ref 14 ClinicalTrials.gov (NCT00765973) Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
Ref 16 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
Ref 17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033866)
Ref 18 ClinicalTrials.gov (NCT04406272) VB-111 in Surgically Accessible Recurrent/Progressive GBM. U.S. National Institutes of Health.
Ref 19 ClinicalTrials.gov (NCT04729608) A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC). U.S.National Institutes of Health.
Ref 20 ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health.
Ref 21 ClinicalTrials.gov (NCT05092360) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7). U.S.National Institutes of Health.
Ref 22 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
Ref 23 ClinicalTrials.gov (NCT05329545) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT). U.S.National Institutes of Health.
Ref 24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 25 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
Ref 26 MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
Ref 27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022740)
Ref 28 Clinical pipeline report, company report or official report of Endocyte.
Ref 29 ClinicalTrials.gov (NCT00477282) Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8275).
Ref 32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020691)
Ref 33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8265).
Ref 34 Clinical pipeline report, company report or official report of BioAtla
Ref 35 Clinical pipeline report, company report or official report of Allarity Therapeutics.
Ref 36 ClinicalTrials.gov (NCT04669002) Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance. U.S.National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT05243524) Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer. U.S.National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT05261490) A Phase 1/2 Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. U.S.National Institutes of Health.
Ref 41 CVAC SHOWS OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER IN PHASE II STUDY. 19 May 2015.
Ref 42 ClinicalTrials.gov (NCT01453361) Phase II FANG in Advanced Melanoma. U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
Ref 44 ClinicalTrials.gov (NCT01118052) EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. U.S. National Institutes ofHealth.
Ref 45 Clinical pipeline report, company report or official report of Galena Biopharma.
Ref 46 ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT02232633) A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer. U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT03878849) Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP (PREDICT 2X-121). U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT03933761) Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE). U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
Ref 52 Dendritic cell-targeted vaccines--hope or hype. Nat Rev Immunol. 2014 Oct;14(10):705-11.
Ref 53 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201379.
Ref 54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8258).
Ref 55 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8405).
Ref 56 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
Ref 58 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7881).
Ref 59 ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
Ref 60 ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT05451849) A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. U.S.National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT04396340) First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b. U.S. National Institutes of Health.
Ref 63 ClinicalTrials.gov (NCT02759588) GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer. U.S. National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT02336984) A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS. U.S. National Institutes of Health.
Ref 65 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 66 2011 Pipeline of Immunovaccine.
Ref 67 ClinicalTrials.gov (NCT03564340) Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 69 ClinicalTrials.gov (NCT00660101) Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer. U.S. National Institutes of Health.
Ref 70 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 71 ClinicalTrials.gov (NCT01648452) CNTF Implants for CNGB3 Achromatopsia. U.S. National Institutes of Health.
Ref 72 ClinicalTrials.gov (NCT00382811) OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 73 ClinicalTrials.gov (NCT00062036) Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma. U.S. National Institutes of Health.
Ref 74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027639)
Ref 75 ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Ref 76 ClinicalTrials.gov (NCT04163094) Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy. U.S.National Institutes of Health.
Ref 77 ClinicalTrials.gov (NCT01248949) A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 78 ClinicalTrials.gov (NCT04406623) Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer. U.S. National Institutes of Health.
Ref 79 Clinical pipeline report, company report or official report of INmune Bio
Ref 80 ClinicalTrials.gov (NCT05107739) A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies. U.S.National Institutes of Health.
Ref 81 ClinicalTrials.gov (NCT04707248) Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors. U.S.National Institutes of Health.
Ref 82 ClinicalTrials.gov (NCT03608618) Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma. U.S. National Institutes of Health.
Ref 83 Clinical pipeline report, company report or official report of Immunotope.
Ref 84 ClinicalTrials.gov (NCT03323398) Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies. U.S. National Institutes of Health.
Ref 85 ClinicalTrials.gov (NCT03839524) A Trial Evaluating TG4050 in Ovarian Carcinoma.. U.S. National Institutes of Health.
Ref 86 ClinicalTrials.gov (NCT04711161) Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. U.S.National Institutes of Health.
Ref 87 ClinicalTrials.gov (NCT05397093) A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT03748186) Study of STRO-002, an Anti-Folate Receptor Alpha (FolRalpha) Antibody Drug Conjugate in Ovarian & Endometrial Cancers. U.S. National Institutes of Health.
Ref 89 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036367)
Ref 90 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023517)
Ref 91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2522).
Ref 92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028960)
Ref 93 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 94 ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
Ref 95 ClinicalTrials.gov (NCT01322802) Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 96 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Ref 97 ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Ref 98 Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 99 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008435)
Ref 100 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 101 ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers
Ref 102 ClinicalTrials.gov (NCT01578564) Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel. U.S. National Institutes of Health.
Ref 103 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037354)
Ref 104 ClinicalTrials.gov (NCT01335958) Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
Ref 105 ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
Ref 106 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin Ther Pat. 2017 Jun;27(6):657-666. doi: 10.1080/13543776.2017.1259412. Epub 2016 Nov 21.
Ref 107 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009455)
Ref 108 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
Ref 109 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014322)
Ref 110 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004939)
Ref 111 R&D Pipeline (February 2011).
Ref 112 ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 113 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020371)
Ref 114 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034152)
Ref 115 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035599)
Ref 116 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013518)
Ref 117 Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med. 1987 Dec;28(12):1807-19.
Ref 118 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 119 Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
Ref 120 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.